MedTrace Logo

Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag

NCT00888901 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-04-20

No results posted yet for this study

Summary

This is a single-center, prospective, controlled study with one eltrombopag treatment group and 2 control groups, one on standard steroid treatment, and another one untreated.

The aim of the study is to determine the effect of Thrombopoietin Receptor (MPL) agonists on shear-induced platelet activation.

Conditions

  • Idiopathic Thrombocytopenic Purpura

Interventions

DRUG

eltrombopag

eltrombopag tablets daily, in increasing dosage, for three months

DRUG

corticosteroids (Aprednislon)

corticosteroids in decreasing dosage

Sponsors & Collaborators

Principal Investigators

  • Ingrid Pabinger, Prof. Dr. · Medical University of Vienna

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-03-31
Completion
2011-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00888901 on ClinicalTrials.gov